SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor Technologies is experiencing a surge as news circulates about a significant government initiative to buy $200 billion in mortgage bonds, aiming to drive down interest rates. The community is buzzing with expectations of a major rally and potential short squeeze, anticipating increased housing transaction volume due to improved affordability. While some express caution about profit-taking, the overwhelming sentiment points to a renewed bullish outlook for the real estate sector.

SMX (Security Matters) Plc is a holding company, which engages in the provision of authentication solutions. It offers brand protection, authentication, and track and trace technology. The company was founded by Haggai Alon on July 1, 2022 and is headquartered in Dublin, Ireland.

SMX (Security Matters) Plc

SMX (Security Matters) PLC

SMX is seeing intense discussion after eliminating its convertible debt, a move that many in the community believe strengthens its balance sheet and removes a key dilution overhang. This catalyst is fueling strong bullish sentiment, with traders actively debating a potential short squeeze due to high cost-to-borrow and limited share availability for the blockchain-enabled traceability company, despite ongoing skepticism regarding its profitability and historical volatility.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix (CRMD) is seeing a sharp decline after releasing preliminary Q4 results and forward guidance, revealing a significant drop in DefenCath revenue post-TDAPA in late 2026, intensified by news of CEO Joe Todisco's compensation increase. This has sparked widespread community frustration, with many retail investors accusing management of short-changing them and questioning recent acquisition strategies. Despite some viewing the sell-off as an overreaction given DefenCath's strong real-world efficacy and pipeline potential, the immediate market sentiment is dominated by concerns over future profitability and leadership actions.

Oscar Health, Inc. is a health insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

Oscar Health is actively discussed amidst political negotiations concerning the extension of Affordable Care Act (ACA) subsidies, with a recent House vote favoring a multi-year extension driving investor attention. The community is sharply divided; optimists foresee a potential short squeeze and significant upside if a bipartisan agreement is reached in the Senate, while others caution about declines if a favorable outcome doesn't materialize. This ongoing debate, coupled with recent analyst attention, places OSCR at the forefront of healthcare sector conversations.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

Crow with Knife ($CAW) is trending due to its robust multi-chain presence across Solana, Base, and Cronos, leveraging LayerZero technology with a deflationary burn mechanism, alongside community excitement around its visibility on platforms like Coinbase. The vibrant community is passionately united by an ambitious vision for $CAW to become the top memecoin, aiming to flip established assets like $DOGE and drive significant volume across the crypto market.

Baidu, Inc. engages in the provision of internet search and online marketing solutions. The firm’s products and services include Baidu App, Baidu Search, Baidu Feed, Haokan, Quanmin, Baidu Post Bar, Baidu Knows, Baidu Encyclopedia, Baidu Input Method Editor or Baidu IME, Baidu AI Cloud and Overseas Products. It operates through the following segments: Baidu Core and iQIYI. The Baidu Core segment provides search-based, feed-based, and other online marketing services. The iQiyi segment is an online entertainment service provider, which offers original, professionally produced and partner-generated content on its platform. The company was founded by Yanhong Li and Xu Yong on January 18, 2000 and is headquartered in Beijing, China.

Baidu Inc - ADR

Baidu is trending as its AI chip unit, Kunlunxin, has confidentially filed for an initial public offering in Hong Kong, aiming to unlock value and enhance its market profile. This strategic move, along with its advancements in autonomous driving and AI models, is sparking community discussion about Baidu's potential revaluation beyond its traditional search business. Investors are actively watching how this development positions the company within China's accelerating push for domestic AI leadership.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending following highly positive FDA feedback, confirming no additional clinical trials are needed for its lead HS therapy, sonelokimab, paving a clear path to regulatory submission. This significant de-risking event has ignited strong community discussion, fueling speculation of an imminent Merck buyout at a substantially higher valuation and expectations of a potential short squeeze as the market fully re-evaluates the stock's intrinsic value.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is generating significant conversation ahead of upcoming Clarity Act discussions, which the community hopes will provide regulatory certainty and enable independent price action. This optimism is fueled by strong institutional interest seen in ETF activity and ongoing speculation around major corporate partnerships, despite some recent price volatility.

Canadian Solar, Inc. engages in the manufacture of solar photovoltaic modules, provision of solar energy and battery storage solutions, and development of utility-scale solar and battery storage products. It operates through the CSI Solar and Global Energy segments. The CSI Solar segment designs, develops, and manufactures solar ingots, wafers, cells, modules, and other solar power and battery storage products. The Global Energy segment includes solar and battery storage project development and sale, asset management services for operational projects, sale of electricity, and investment in retained assets. The company was founded by Shawn Qu in October 2001 and is headquartered in Kitchener, Canada.

Canadian Solar Inc

Canadian Solar is trending sharply downward following its announcement of a $200 million convertible notes offering, which many shareholders view as dilutive and a "fraudulent" move orchestrated to benefit short positions. This controversial financing has intensified community accusations of market manipulation and insider trading, even as underlying discussions highlight the company's strategic U.S. manufacturing expansion and ongoing speculation about a potential multi-billion dollar sale of its Recurrent Energy unit.

Rocket Cos., Inc. engages in the provision of a suite of services related to homeownership and other personal financial transactions. It operates through the following segments: Direct to Consumer and Partner Network. The Direct to Consumer segment consists of performance marketing and direct engagement through the Rocket Mortgage App. The Partner Network Segment focuses on partnerships with premier consumer-focused organizations, brokers and mortgage professionals who leverage the platform and scale to provide mortgage solutions to clients. The company was founded by Daniel Gilbert in 1985 and is headquartered in Detroit, MI.

Rocket Companies Inc - Ordinary Shares Class A

Rocket Companies is experiencing strong trending activity, fueled by a prominent political figure's pledge to lower mortgage rates and inject substantial capital into the housing market. The community is highly bullish, anticipating a significant refinance boom and potential short squeeze, with many viewing RKT's integrated platform and strategic acquisitions as key advantages for substantial upside in the evolving mortgage sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$PFE 8 cancer blockbuster drugs (yes, 8) coming by 2030. Pfizer will be THE leader in cancer treatment. That&#39;s all you need to know.  
https://www.fiercepharma.com/pharma/pfizer-expects-its-8-blockbuster-cancer-drugs-come-each-4-focus-areas-exec#:~:text=Pfizer%20expects%208%20blockbuster%20cancer,of%204%20focus%20areas%3A%20exec&amp;text=During%20a%20recent%20investor%20event,short%20of%20naming%20specific%20products.

Karina

Gary Hoffman

Jai Krishen Hakim

Stephen

David

Fiercepharma

StockTwits Web

Pfizer Inc

 8 cancer blockbuster drugs (yes, 8) coming by 2030. Pfizer will be THE leader in cancer treatment. That's all you need to know.  
